Pharmaceuticals to Experience Wide Changes - In-Depth Research Featuring Novavax and Radient Pharmaceuticals

Mar 03, 2011, 08:59 ET from World Street Fundamentals

HONG KONG, March 3 /PRNewswire/ - Today, www.WorldStreetFundamentals.com released its industry report highlighting Novavax, Inc. (NASDAQ: NVAX) and Radient Pharmaceuticals Corporation (AMEX: RPC). Investors from around the world are invited to view fundamental and technical analysis at www.WorldStreetFundamentals.com/Reports.php.  

The global pharmaceutical market is expected to experience wide changes, with trends growing towards the Asia-Pacific region. A favorable regulatory environment has started to emerge in India, China, Malaysia, South Korea and Indonesia; drawing the attention of larger API product providers. This new competition within an already fast-paced economy has closed the gap between product cost and disposable income of consumers - a change that is expected to drive long-term growth within the global marketplace. Global pharmaceutical market sales are expected to grow at a 4 - 7% compound annual growth rate (CAGR) through 2013, largely driven via growing access to health-care in emerging economic regions. Short-term growth within the sector will be fueled by the US market, as it remains the largest pharmaceutical market in the world. A large focus on R&D in biotechnology, special drugs and generic drugs will remain a strong catalyst to meet 2011 targets of $315 billion dollar in sales volume within the United States alone. 

World Street Fundamentals has highlighted Novavax for its recently awarded contract for $97 Million dollars by the U.S. Department of Health and Human Services (HHS). The company's technology platform is based on virus-like particles (VLPs) using insect cells for production, rather than mammalian eggs, resulting in a low-cost disposable system with quick-response deployment potential. To read the report on Novavax, Inc. (NASDAQ: NVAX), click here: www.WorldStreetFundamentals.com/ViewFullReport.NVAX.php

World Street has recognized Radient Pharmaceuticals for its lead product, a FDA approved cancer test kit marketed as Onko-Sure. Recently, Radient has begun repositioning itself in order for it to become solely focused on distributing its cancer test to market. Estimated market projections for cancer test kits are as high as $1.45 billion annually. To read the report on Radient Pharmaceuticals Corporation (AMEX: RPC), click here: www.WorldStreetFundamentals.com/ViewFullReport.RPC.php

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets around the world. Covering the top performers in the hottest sectors and providing clarity to investors around the world.

SOURCE World Street Fundamentals